Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen Chia

Showing results (81-90 of 104) with videos related to

Pageof 11
Sort By:
Cancer Research|March 19, 2011
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitorsYuanmei Lou, Paul C McDonald, Arusha Oloumi, et al.
The New England Journal of Medicine|December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast CancerDennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Nature Communications|August 4, 2022
Accurate determination of CRISPR-mediated gene fitness in transplantable tumoursPeter Eirew, Ciara O'Flanagan, Jerome Ting, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Nature|August 26, 2021
Genome of a middle Holocene hunter-gatherer from WallaceaSelina Carlhoff, Akin Duli, Kathrin Nägele, et al.
Pageof 11

Showing results (81-90 of 104) with videos related to

Sort By:
Pageof 11
Cancer Research|March 19, 2011
Targeting tumor hypoxia: suppression of breast tumor growth and metastasis by novel carbonic anhydrase IX inhibitorsYuanmei Lou, Paul C McDonald, Arusha Oloumi, et al.
The New England Journal of Medicine|December 12, 2019
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast CancerDennis J Slamon, Patrick Neven, Stephen Chia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 5, 2018
Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3Dennis J Slamon, Patrick Neven, Stephen Chia, et al.
Breast Cancer Research and Treatment|April 11, 2020
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapyKarin Ribi, Weixiu Luo, Barbara A Walley, et al.
Nature Communications|August 4, 2022
Accurate determination of CRISPR-mediated gene fitness in transplantable tumoursPeter Eirew, Ciara O'Flanagan, Jerome Ting, et al.
The Lancet. Oncology|June 4, 2017
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trialJosé Baselga, Seock-Ah Im, Hiroji Iwata, et al.
JAMA Oncology|April 12, 2019
Current Landscape of Immunotherapy in Breast Cancer: A ReviewSylvia Adams, Margaret E Gatti-Mays, Kevin Kalinsky, et al.
The New England Journal of Medicine|June 2, 2025
First-Line Camizestrant for Emerging <i>ESR1</i>-Mutated Advanced Breast CancerFrançois-Clément Bidard, Erica L Mayer, Yeon Hee Park, et al.
The Oncologist|April 25, 2015
Defining breast cancer intrinsic subtypes by quantitative receptor expressionMaggie C U Cheang, Miguel Martin, Torsten O Nielsen, et al.
Nature|August 26, 2021
Genome of a middle Holocene hunter-gatherer from WallaceaSelina Carlhoff, Akin Duli, Kathrin Nägele, et al.
Pageof 11